The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy

References

• Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification: a problem reduced but not yet eradicated. Arch Ophtalmol 2009; 127: 555–562.
   PubMed Web of Science ®Google Scholar
• Steinert RF, Puliafito CA, Kumar SR, et al. Cystoid macular edema, retinal detachment, and glaucoma after Nd: yAGlaser posterior capsulotomy. Am J Ophthalmol 1991; 112: 373–380.
   PubMed Web of Science ®Google Scholar
• Channell MM, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol (Chicago, Ill : 1960) 1984; 102: 1024–1026.
   Google Scholar
• Richter CU, Arzeno G, Pappas HR, et al. Prevention of intraocular pressure elevation following neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol (Chicago, Ill : 1960) 1985; 103: 912–915.
   Google Scholar
• Richter CU, Arzeno G, Pappas HR, et al. Intraocular pressure elevation following Nd: yAGlaser posterior capsulotomy. Ophthalmology 1985; 92: 636–640.
   Web of Science ®Google Scholar
• Slomovic AR, Parrish RK 2nd. Acute elevations of intraocular pressure following Nd: YAGlaser posterior capsulotomy. Ophthalmology 1985; 92: 973–976.
   PubMed Web of Science ®Google Scholar
• Flohr MJ, Robin AL, Kelley JS. Early complications following Q-switched neodymium: YAG laser posterior capsulotomy. Ophthalmology 1985; 92: 360–363.
   Web of Science ®Google Scholar
• Chen TC, Ang RT, Grosskreutz CL, et al. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology 2001; 108: 1033–1038.
   Web of Science ®Google Scholar
• Chevrier RL, Assalian A, Duperré J, et al. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg Lasers 1999; 30: 199–204.
   Google Scholar
• Gartaganis SP, Mela EK, Katsimpris JM, et al. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laserposterior capsulotomy. Ophthalmic Surg Lasers 1999; 30: 647–652.
   Google Scholar
• Seong GJ, Lee YG, Lee JH, et al. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd: YAGlaser posterior capsulotomy. Ophthalmic Surg Lasers 2000; 31: 308–314.
   Google Scholar
• Yeom HY, Lee JH, Hong YJ, et al. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd: YAGlaser posterior capsulotomy. J Ocul Pharmacol Ther 2006; 22: 176–181.
   Web of Science ®Google Scholar
• Artunay O, Yuzbasioglu E, Unal M, et al. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium: yttrium–aluminum–garnet laser posterior capsulotomy. J Ocul Pharmacol Ther 2010; 26: 513–517.
   Web of Science ®Google Scholar
• Brown SV, Thomas JV, Belcher CD 3rd, et al. Effect of pilocarpine in treatment of intraocular pressure elevation following neodymium: YAG laser posterior capsulotomy. Ophthalmology 1985; 92: 354–359.
   PubMed Web of Science ®Google Scholar
• Cai JP, Cheng JW, Wei RL, et al. Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy. Int Ophthalmol 2008; 28: 19–22.
   PubMedGoogle Scholar
• Ladas ID, Baltatzis S, Panagiotidis D, et al. Topical 2.0% dorzolamide vs oral Acetazolamide for prevention of intraocular pressure rise after neodymium: yAGlaser posterior capsulotomy. Arch Ophthalmol (Chicago, Ill : 1960) 1997; 115: 1241–1244.
   Google Scholar
• Ladas ID, Pavlopoulos GP, Kokolakis SN, et al. Prophylactic use of Acetazolamide to prevent intraocular pressure elevation following Nd-YAG laser posterior capsulotomy. Br J Ophthalmol 1993; 77: 136–138.
   PubMed Web of Science ®Google Scholar
• Rakofsky S, Koch DD, Faulkner JD, et al. Levobunolol 0.5% and timolol 0.5% to prevent intraocular pressure elevation after neodymium: YAGlaser posterior capsulotomy. J Cataract Refract Surg 1997; 23: 1075–1080.
   Web of Science ®Google Scholar
• Unal M, Yücel I, Akar Y. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium: YAGlaser posterior capsulotomy. J Cataract Refract Surg 2006; 32: 1499–1502.
   PubMed Web of Science ®Google Scholar
• Arieta C, Amaral M, Matuda E, et al. Dorzolamide X apraclonidine in the prevention of the intraocular pressure spike after Nd : YAG laser posterior capsulotomy. Curr Eye Res 2002; 25: 237–241.
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol 1993; 9: 373–384.
   PubMedGoogle Scholar
• van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177–1185.
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999; 128: 8–14.
   PubMed Web of Science ®Google Scholar
• Hopf S, Mercieca K, Pfeiffer N, et al. Brimonidine-associated uveitis - a descriptive case series. BMC Ophthalmol 2020; 20: 489.
   Web of Science ®Google Scholar
• Kim JM, Park KH, Han SY, et al. Changes in intraocular pressure after pharmacologic pupil dilation. BMC Ophthalmol 2012; 12: 53.
   Web of Science ®Google Scholar
• Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The brimonidine study group III. Surv Ophthalmol 1996; 41(Suppl 1): S39–47.
   PubMed Web of Science ®Google Scholar